PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
34.37%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
0.63%
D&A growth of 0.63% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-79.79%
Both cut yoy SBC, with RVPH at -56.99%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-121.40%
Negative yoy working capital usage while RVPH is 125.07%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-200.00%
Negative yoy AP while RVPH is 101.70%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-91.42%
Negative yoy usage while RVPH is 159.63%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2.52%
Lower 'other non-cash' growth vs. RVPH's 81.82%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-18.12%
Negative yoy CFO while RVPH is 38.83%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while RVPH is 4129.39%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.